𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B

✍ Scribed by Satoshi Shakado; Hiroshi Watanabe; Takashi Tanaka; Daisuke Morihara; Shinya Nishizawa; Shinjiro Inomata; Syuichi Ueda; Teruo Matsumoto; Akira Anan; Yasuaki Takeyama; Makoto Irie; Kaoru Iwata; Tetsuro Sohda; Shotaro Sakisaka

Book ID
107593779
Publisher
Springer-Verlag
Year
2008
Tongue
English
Weight
251 KB
Volume
2
Category
Article
ISSN
1936-0533

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adefovir-based combination therapy with
Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B
✍ Soon Sun Kim; Jae Youn Cheong; Dami Lee; Myoung Hee Lee; Sun Pyo Hong; Soo-Ok Ki 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

This study evaluated the efficacy of adefovir (ADV) plus lamivudine (LAM) or ADV add-on therapy for patients with entecavir (ETV)-refractory hepatitis B infection. Twenty-nine ETVresistant and 8 patients with suboptimal response to ETV were enrolled. Twenty-seven patients received ADV þ LAM therapy

Dynamics of lamivudine-resistant hepatit
Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy
✍ Samreen Ijaz; Catherine Arnold; Samir Dervisevic; Jana Mechurova; Nick Tatman; R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

## Abstract Adefovir dipivoxil has been used alone or together with lamivudine to suppress lamivudine‐resistant hepatitis B virus (HBV). However, the dynamics of HBV populations under different selection pressures and their impact on treatment outcome are poorly understood. Pyrosequencing® was appl

Clinical course and predictive factors o
Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients
✍ Mashu Aizawa; Akihito Tsubota; Kiyotaka Fujise; Keiko Tatsuzawa; Midori Kono; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract The aims of this study were to assess the long‐term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV‐DNA <2.6 log copies/ml at 12 months of

Efficacy of adefovir add-on lamivudine r
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B
✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45

Efficacy of entecavir in patients with c
Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone
✍ Ju Hyun Shim; Dong Jin Suh; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/